Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) EPS (Weighted Average and Diluted) (2021 - 2025)

Arcturus Therapeutics Holdings' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$1.05 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 5.41% year-over-year to -$1.05; the TTM value through Dec 2025 reached -$2.4, up 20.27%, while the annual FY2025 figure was -$2.4, 20.0% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.05 in Q4 2025 per ARCT's latest filing, down from -$0.49 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $4.44 in Q4 2022 to a low of -$2.07 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.62, with a median of -$0.82 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 402.04% in 2022, then plummeted 153.48% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.47 in 2021, then skyrocketed by 402.04% to $4.44 in 2022, then tumbled by 109.91% to -$0.44 in 2023, then tumbled by 152.27% to -$1.11 in 2024, then rose by 5.41% to -$1.05 in 2025.
  • Per Business Quant, the three most recent readings for ARCT's EPS (Weighted Average and Diluted) are -$1.05 (Q4 2025), -$0.49 (Q3 2025), and -$0.34 (Q2 2025).